Received: 24 October 2019
Accepted: 26 April 2021
First Online: 5 May 2021
: Given that the data used in this study will be published and anonymised, publicly available and peer reviewed, ethical approval is not a requirement for this study. This review will be reported in line with the PRISMA statement and will include the PRISMA Checklist. The findings will be published in a peer-reviewed journal.
: Not applicable.
: Kota Katanoda has been an expert committee member of the Pharmaceuticals and Medical Devices Agency since 2019. The authors declare that they have no competing interests.